LOS ANGELES, CA - August 4, 2026 (NEWMEDIAWIRE) - SRX Global (NYSE American: SRXH) announced that it has acquired a stake in Vistagen Therapeutics, a late clinical-stage biopharmaceutical company developing intranasal neuroscience therapies based on its proprietary pherine platform. SRX said the investment aligns with its strategy of creating long-term shareholder value through investments in high-conviction operating companies and strategic assets.

SRX said it believes Vistagen shares are undervalued and intends to engage constructively with the company’s leadership team and board of directors to discuss opportunities to unlock shareholder value.

To view the full press release, visit https://ibn.fm/NEczV

About SRX Global Inc.

SRX Global is an AI-driven platform focused on generating long-term shareholder value through investments in high-conviction operating companies, strategic assets, and technology-enabled opportunities. The Company leverages proprietary technology, data analytics, and disciplined capital allocation to identify and manage investments across multiple sectors.

For more information on the company, please visit: www.SRXGlobalInc.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward Looking Statements

Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law.

View the original release on www.newmediawire.com

This contant was orignally distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is SRX Global (SRXH) Acquires Stake in Vistagen Therapeutics.